Log in to search using one of your social media accounts:

 

Orexo nabs regulatory win for fast-dissolving opioid dependence therapy
Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence. The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company. Get the full story at our sister site, Drug Delivery Business News. The post Orexo nabs regulatory win for fast-dissolving opioid dependence therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Orexo AB Source Type: news

Long- and Short-Acting Opioid Addiction Meds Equally Effective Long- and Short-Acting Opioid Addiction Meds Equally Effective
Extended-release naltrexone and buprenorphine/naloxone are similarly efficacious in preventing relapse for patients with opioid use disorder, although naltrexone was more difficult to initiate.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone. Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has do...
Source: JEMS Patient Care - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone. Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has do...
Source: JEMS: Journal of Emergency Medical Services News - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Study: Head-to-head comparison of opioid use disorder therapies finds similarities
A study published today in The Lancet found that two different therapies used to treat opioid use disorder – an extended-release naltrexone injection and a combination of buprenorphine and naloxone – have similar outcomes once patients get past the hurdle of starting treatment. This is the first study to compare the combination therapy and naltrexone head-to-head in the U.S. The study enrolled 570 opioid-dependent adults, 82% of which were using heroin and 16% of which were abusing pain medications. Get the full story at our sister site, Drug Delivery Business News. The post Study: Head-to-head c...
Source: Mass Device - November 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development National Institutes of Health (NIH) Source Type: news

Opioid treatment drugs have similar outcomes once patients initiate treatment
NIDA study compares buprenorphine/naloxone combination to extended release naltrexone. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 14, 2017 Category: American Health Source Type: news

Opioid treatment drugs have similar outcomes once patients initiate treatment
A study comparing the effectiveness of two pharmacologically distinct medications used to treat opioid use disorder – a buprenorphine/naloxone combination and an extended release naltrexone formulation – shows similar outcomes once medication treatment is initiated. Among active opioid users,... (Source: NIDA News)
Source: NIDA News - November 14, 2017 Category: Addiction Tags: Health and Medical Professionals, Heroin, Opioids, Researchers, Treatment Research Source Type: news

Pediatricians ’ Counseling Hopes To End Teen Opioid Addiction Before It Starts
WAREHAM (CBS) – One out of every four teenagers admits to misusing or abusing, a prescription drug. It’s a dangerous road that can lead to addiction. To prevent and treat drug-use in kids there is now a first-of-its-kind program tackling the issue head-on right at the pediatrician’s office. At Wareham Pediatrics, the Cat in the Hat welcomes young patients and route markers provide a guide to the exam rooms. (WBZ-TV) But the practice itself could be creating a road map to prevent and treat addiction in kids. (WBZ-TV) “It was a really helpless feeling to sometimes see kids and families struggling with...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 24, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Boston Children's Hospital Confronting The Crisis Lisa Hughes opioid crisis Suboxone Source Type: news

Opioid Blocker as Good as Suboxone in First Head-to-Head Trial (CME/CE)
(MedPage Today) -- Monthly naltrexone (Vivitrol) non-inferior to buprenorphine/naloxone (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - October 20, 2017 Category: Anesthesiology Source Type: news

Extended-Release Naltrexone Seems as Effective as Standard Treatment for Opioid Dependence (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD Injectable extended-release naltrexone (Vivitrol) appears to be as safe and effective as daily oral buprenorphine-naloxone for treating opioid dependence, according to a Norway-based, noninferiority trial … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 19, 2017 Category: Primary Care Source Type: news

CHMP Backs Two Drugs for Opioid Abuse CHMP Backs Two Drugs for Opioid Abuse
The EMA committee recommends naloxone nasal spray (Nyxoid) for treatment of opioid overdose and buprenorphine plus naloxone sublingual tablets (Zubsolv) for treatment of opioid dependence.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Addressing stigma in medication treatment of adolescents with opioid use disorder - Bagley SM, Hadland SE, Carney BL, Saitz R.
: In September 2016, the American Academic of Pediatrics released a policy statement that adolescents with opioid use disorder should be offered pharmacotherapy with buprenorphine/naloxone, methadone, or naltrexone. In our clinical practice, however, we ha... (Source: SafetyLit)
Source: SafetyLit - August 7, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Rapid Growth in Medicaid Spending on Medications to Treat Opioid Use Disorder and Overdose (June 2017)
Report used state Medicaid drug utilization files from 2011 to 2016 to assess spending on buprenorphine, naltrexone, and naloxone prescriptions. (Source: HSR Information Central)
Source: HSR Information Central - July 11, 2017 Category: International Medicine & Public Health Source Type: news

Heroin Addiction: How My Father Saved Me
I was a breech birth ― feet first, my head got stuck in the birth canal. My father brought me to Children’s Hospital in Boston. The doctors diagnosed me with Cerebral Palsy. They told him that the loss of oxygen to my brain had destroyed a portion of the frontal lobe. But my father was a tough Irish Catholic, old-school warrior. He refused to listen to them. No son of his was going to be a cripple. He found a doctor that told him how he could take the place of my injured brain. Every day, he laid me on the floor and exercised my legs. The muscles in my right leg were all shrunken and twisted. His job was to straigh...
Source: Healthy Living - The Huffington Post - June 16, 2017 Category: Consumer Health News Source Type: news

'All Scientific Hands On Deck' To End The Opioid Crisis
By Nora Volkow (Director, NIDA) and Francis Collins (Director, NIH) In 2015, 2 million people had a prescription opioid use disorder and 591,000 suffered from a heroin use disorder; prescription drug misuse alone cost the nation $78.5 billion in health care, law enforcement, and lost productivity. But while the scope of the crisis is staggering, it is not hopeless. We understand opioid addiction better than many other drug use disorders; there are effective strategies that can be implemented right now to save lives and to prevent and treat opioid addiction. At the National Rx Drug Abuse and Heroin Summit in Atlanta, GA las...
Source: Healthy Living - The Huffington Post - June 1, 2017 Category: Consumer Health News Source Type: news

Trump's Approach To The Opioid Epidemic: Neglect Treatment, Ignore The Experts
WASHINGTON – Since taking office, President Donald Trump has systematically removed or limited the power of federal officials and government offices that have the expertise to confront the nation’s opioid epidemic. Trump asked Surgeon General Vivek Murthy to resign in late April. He still has an acting director running the Centers for Disease Control and Prevention. Although he backtracked on his reported plan to essentially gut his Office of National Drug Control Policy, staffers would be wise to polish their resumes.  Trump’s new budget proposal cuts all federal drug prevention programs by roughly...
Source: Healthy Living - The Huffington Post - May 24, 2017 Category: Consumer Health News Source Type: news

FDA OKs Bunavail for Induction of Opioid Addiction Treatment FDA OKs Bunavail for Induction of Opioid Addiction Treatment
The FDA has broadened the indication for Bunavail (buprenorphine and naloxone) buccal film to include induction of buprenorphine treatment for opioid dependence.FDA Approvals (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 2, 2017 Category: Psychiatry Tags: Pharmacist News Alert Source Type: news

FDA OKs BioDelivery Sciences ’ Bunavail opioid dependence film
BioDelivery Sciences International (NSDQ:BDSI) said today that the FDA approved a supplemental new drug application for its Bunavail buprenorphine and naloxone buccal film. The revised indication allows patients to use the product to initiate buprenorphine treatment for opioid dependence. Induction is the initial process by which a patient transitions from abusing an opioid to buprenorphine treatment which is designed to relieve cravings and withdrawal, according to BioDelivery Sciences. Get the full story at our sister site, Drug Delivery Business News. The post FDA OKs BioDelivery Sciences’ Bunavail opioid dependen...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat BioDelivery Sciences International Source Type: news

These Are The 2 Key Ways People Get Hooked On Prescription Opioids
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.  -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - March 23, 2017 Category: Consumer Health News Source Type: news

ARS adding clinics, prescribers to meet opioid treatment demand
Accessible Recovery Services, a Pittsburgh-based network of a dozen medically assisted opioid treatment clinics across the state, said it plans to add six more sites and dozens of "extenders" — nurse practitioners and physician assistants able to prescribe drugs like buprenorphine — in the next three to four months to meet demand. Dr. Frank Kunkel, president and CEO of ARS, said the clinics serve roughly 7,000 patients per year, providing access to drugs like suboxone and buprenorph ine, opioids… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 23, 2017 Category: Biotechnology Authors: Lydia Nuzum Source Type: news

Hardly Any Teens Receive Effective Treatment For Opioid Addiction
(Reuters Health) - Just a small fraction of adolescents with opioid addiction will receive medications that can help them quit, new research shows. These medications, usually methadone or suboxone, are prescribed to reduce craving for opiates and ease withdrawal symptoms, and studies show they help opiate users to abstain. In 2016, the American Academy of Pediatrics advised doctors to consider medication-assisted treatment, specifically suboxone, for adolescents with “severe opioid use disorders.” To get a “baseline” sense of medication-assisted treatment in adolescents with opiate or heroin addicti...
Source: Healthy Living - The Huffington Post - March 13, 2017 Category: Consumer Health News Source Type: news

Obamacare Repeal Could Cripple Efforts To Combat The Opioid Epidemic
WASHINGTON ― Repealing the Affordable Care Act would deal a major blow to efforts to fight addiction in one of the states hardest hit by the opioid epidemic, according to a new study from Harvard Medical School and New York University. Across the country, some four million Americans with addictions or mental health disorders could lose their health insurance, greatly diminishing access to life-saving treatments, the researchers found. In Kentucky, the effects of ACA repeal would be especially devastating. The end of Obamacare could cost Kentucky more than 44 percent of its funding for medication-assisted treatm...
Source: Healthy Living - The Huffington Post - February 14, 2017 Category: Consumer Health News Source Type: news

Inside a Killer Drug Epidemic: A Look at America ’ s Opioid Crisis
The opioid epidemic killed more than 33,000 people in 2015. What follows are stories of a national affliction that has swept the country, from cities on the West Coast to bedroom communities in the Northeast. (Source: NYT Health)
Source: NYT Health - January 6, 2017 Category: Consumer Health News Tags: Heroin Addiction (Psychology) Buprenorphine (Drug) Naloxone (Drug) Sinaloa Cartel Seattle (Wash) Milwaukee (Wis) Iowa New England States (US) Utah Source Type: news

Snapshots of an Epidemic: A Look at the Opioid Crisis Across the Country
The opioid epidemic killed more than 33,000 people in 2015. What follows are stories of a national affliction that has swept the country, from cities on the West Coast to bedroom communities in the Northeast. (Source: NYT Health)
Source: NYT Health - January 6, 2017 Category: Consumer Health News Tags: Heroin Addiction (Psychology) Buprenorphine (Drug) Naloxone (Drug) Sinaloa Cartel Seattle (Wash) Milwaukee (Wis) Iowa New England States (US) Utah Source Type: news

Orexo Appeals Zubsolv(R) US District Court Decision
UPPSALA, Sweden, Dec 8, 2016 -- (Healthcare Sales & Marketing Network) -- Orexo AB (publ.) announces that it has appealed the decision rendered by the United States District Court for the District of Delaware on November 15, 2016 regarding the validity of... Biopharmaceuticals, Generics, Litigation Orexo, Zubsolv, buprenorphine, naloxone, Actavis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 8, 2016 Category: Pharmaceuticals Source Type: news

At the Frontline of the Opioid Epidemic, but Unable to Help
People seek out the emergency room to get painkillers, but the E.R. remains one of the hardest places to get help for an addiction. (Source: NYT Health)
Source: NYT Health - November 10, 2016 Category: Consumer Health News Authors: HELEN OUYANG, M.D. Tags: Addiction (Psychology) Pain-Relieving Drugs Emergency Medical Treatment Drug Abuse and Traffic Hospitals Buprenorphine (Drug) Naloxone (Drug) OxyContin (Drug) Source Type: news

Houston Concierge Medicine Now Offering Outpatient Drug Rehab...
Houston Concierge Medicine and Wellness is now offering outpatient drug rehab therapy with Suboxone. The therapy is highly effective for helping patients who want to get off of opiates as an...(PRWeb November 03, 2016)Read the full story at http://www.prweb.com/releases/suboxonedoctorshouston/outpatientdrugrehab/prweb13821692.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 3, 2016 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
MORRISTOWN, N.J., Oct. 6, 2016 -- (Healthcare Sales & Marketing Network) -- Orexo US announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) 0.7mg/0.18mg for the treatment ... Biopharmaceuticals, FDA Orexo, ZUBSOLV, buprenorphine, naloxone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 6, 2016 Category: Pharmaceuticals Source Type: news

Canadian Doctors Can Now Prescribe Heroin
Canadian doctors can now prescribe heroin to people with serious addictions to the drug. This change is thanks to new regulations approved earlier this month by the Canadian government. The government says this treatment will be limited to a small number of users "in cases where traditional options have been tried and proven ineffective." Doctors will need to apply to Health Canada -- the country's health department -- for access to pharmaceutical grade heroin (diacetylmorphine). Requests will be approved on a case-by-case basis as part of the government-run Special Access Programme. Shift in approach This ...
Source: Healthy Living - The Huffington Post - September 27, 2016 Category: Consumer Health News Source Type: news

35 States File'Product Hopping' Lawsuit Against Indivior
British opiod drugmaker Indivior is facing lawsuits from 35 U.S. states alleging it employed a product hopping strategy to keep generic versions of Suboxone off the market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 24, 2016 Category: Pharmaceuticals Source Type: news

States sue Suboxone drugmaker
A lawsuit filed by 35 states and the District of Columbia alleges that drugmaker Indivior violated antitrust laws by trying to extend its monopoly over Suboxone, New York's attorney general announced Thursday. Suboxone is a prescription drug used to treat patients addicted to heroin, painkillers and other opioid drugs. (Source: CNN.com - Health)
Source: CNN.com - Health - September 23, 2016 Category: Consumer Health News Source Type: news

Suboxone maker sued by U.S. states alleging anticompetitive practices
35 U.S. states and District of Columbia file an antitrust lawsuit alleging that British drugmaker Indivior tried to keep cheaper, generic versions of Suboxone off the market. (Source: CBC | Health)
Source: CBC | Health - September 23, 2016 Category: Consumer Health News Tags: News/Health Source Type: news

Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
PHILADELPHIA, Sept. 20, 2016 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Buprenorphi... Biopharmaceuticals, Generics, FDA Lannett, Buprenorphine, Naloxone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 20, 2016 Category: Pharmaceuticals Source Type: news

Dependence on over the counter (OTC) codeine containing analgesics: treatment and recovery with buprenorphine naloxone - Hout MCV, Delargy I, Ryan G, Flanagan S, Gallagher H.
We present a clinical case series of four adult patients dependent on OTC codeine combination analgesics in Ireland. Cases (... (Source: SafetyLit)
Source: SafetyLit - September 19, 2016 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Physician efforts to reverse opioid epidemic quantified
When patients present with issues, physicians look to the most effective tools for treatment. The same is true in addressing an epidemic. While much more work remains to reverse the nation ’s opioid epidemic, using tools such as prescription drug monitoring programs (PDMP), medication-assisted treatment and naloxone, physicians are making progress. A new fact sheet provides some evidence of that progress on a number of fronts.Focused prescribing practices In a fact sheet released by the AMA,physicians ’ progress to reverse the nation’s opioid epidemic was quantified showing new trends in the use of avail...
Source: AMA Wire - September 14, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news

HHS: Medication Assisted Treatment for Opioid Use Disorders; Correction
Correction made to afinal rule that appeared in the Federal Register on July 8, 2016 regarding increased access to treatment with buprenorphine and buprenorphine/naloxone. HHS mistakenly listed the American Osteopathic Academy of Addiction Medicine (AOAAM) as an approved credentialing organization when they intended to reference the American Osteopathic Association (AOA). (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - September 9, 2016 Category: Rural Health Source Type: news

Words matter: The language of addiction and life-saving treatments
News articles, radio, and television frequently report on the current opioid crisis. As the death toll has mounted, the media has importantly covered many aspects of the crisis. Unfortunately, this coverage often focuses on the very visible individuals who continue to struggle with active addiction. What is missing is a narrative of hope for a chronic disease which is as treatable as diabetes or high blood pressure. In addition to the pessimistic portrait painted about addiction, the language used by the media is often problematic. Articles frequently use the term “abuse” or “abuser” or refer to ind...
Source: New Harvard Health Information - August 15, 2016 Category: Consumer Health News Authors: Sarah Wakeman, MD, FASAM, Medical Director, Massachusetts General Hospital Substance Use Disorder Initiative Tags: Addiction Behavioral Health Pain Management Source Type: news

Some good news on opioid epidemic: Treatment options are expanding
This article was originally published on The Conversation. Read the original article. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - August 10, 2016 Category: Consumer Health News Source Type: news

Fentanyl: The dangers of this potent “ man-made ” opioid
As we watch the devastation of the opioid crisis escalate in a rising tide of deaths, a lesser known substance is frequently mentioned: fentanyl. Fentanyl’s relative obscurity was shattered with the well-publicized overdose death of pop star Prince. Previously used only as a pharmaceutical painkiller for crippling pain at the end of life or for surgical procedures, fentanyl is now making headlines as the drug responsible for a growing proportion of overdose deaths. So what is fentanyl and why is it so dangerous? Fentanyl is a synthetic opioid, meaning it is made in a laboratory but acts on the same receptors in the b...
Source: New Harvard Health Information - August 5, 2016 Category: Consumer Health News Authors: Sarah Wakeman, MD, FASAM, Medical Director, Massachusetts General Hospital Substance Use Disorder Initiative Tags: Addiction Behavioral Health Brain and cognitive health Pain Management Prevention Source Type: news

Suboxone (Buprenorphine HCl and naloxone HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2016 Category: Drugs & Pharmacology Source Type: news

Bunavail (Buprenorphine and Naloxone Buccal Film) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 22, 2016 Category: Drugs & Pharmacology Source Type: news

Opioid abusers missing out on addiction-fighting drug
Dennis Thompson, HealthDay News Doctors aren't using one of the most effective weapons in battling addiction to prescription painkillers -- the anti-addiction drug Suboxone, a new study finds. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 20, 2016 Category: Consumer Health News Source Type: news

Suboxone Underused, Opioids Overused in Medicare
(MedPage Today) -- Medicare patients who are addicted to opioids may not be getting the help they need (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 20, 2016 Category: Geriatrics Source Type: news

Study examines opioid agonist therapy use in Medicare patients
Few Medicare enrollees appear to be receiving buprenorphine-naloxone, the only opioid agonist therapy for opioid addiction available through Medicare Part D prescription drug coverage, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 20, 2016 Category: Science Source Type: news

Opioid Abusers Missing Out on Addiction-Fighting Drug
WEDNESDAY, July 20, 2016 -- Doctors aren't using one of the most effective weapons at their disposal in battling addiction to prescription painkillers -- the anti-addiction drug Suboxone, a new study finds. A review of Medicare claims showed that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2016 Category: Journals (General) Source Type: news

Treating Drug Addiction With Drugs
The old saying goes that you have to fight fire with fire. Using that logic, health officials have increased the availability of an opioid to combat the rising tide of opiate addiction. On any given day, according to the U.S. Centers for Disease Control and Prevention (CDC), 650,000 opioid prescriptions are dispensed. Of these, 3,900 people begin using the drugs for nonmedical reasons, and 78 people die from an opioid-related overdose. That's every day. In western Pennsylvania, for instance, deaths caused by opioids, including heroin and prescription drugs, increased by more than a third last year, according to a new r...
Source: Healthy Living - The Huffington Post - July 18, 2016 Category: Consumer Health News Source Type: news

How one physician uses his PDMP to help patients
Prescription drug monitoring programs (PDMP) can be an effective clinical tool to assist physicians in making prescribing decisions. Effective PDMPs can help identify red flags in prescription use, and provide information when assessing and making treatment decisions. Learn how one physician in New York uses his PDMP to inform treatment options and discuss safety issues with patients. What a PDMP can do for patients and physicians “The bottom line is that New York’s PDMP is a good tool to use to get some information for your assessment and discussion with your patient,” said Frank Dowling, MD, clinica...
Source: AMA Wire - July 10, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news

HHS: Medication Assisted Treatment for Opioid Use Disorders
This final rule increases access to treatment with buprenorphine and buprenorphine/naloxone, allows eligible practitioners to request approval to treat up to 275 patients, and includes requirements to minimize the risk that medications provided for treatment will be misused or diverted. This rule is effective August 8, 2016. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - July 8, 2016 Category: Rural Health Source Type: news

Portland addictions specialists welcome Feds’ move to ease treatment restrictions
The Obama administration announced it is expanding access to a drug used to treat opioid addiction by raising the cap on how many patients a doctor can treat. Doctors will soon be able to treat 275 patients at a time with buprenorphine, up from 100 currently. The drug, which goes by the brand name Suboxone, helps patients control withdrawal symptoms and cravings for prescription painkillers and heroin alike but doesn’t get them high. About 650,000 Americans received buprenorphine in 2014, according… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 6, 2016 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news